Arterial hypertension is well-known strong risk factor that can lead to the development of coronary artery disease, heart attacks, heart failure, stroke, and other heart-related issues. Arterial hypertension has increased exponentially in the last few decades in adult men and women. Traditionally arterial hypertension is classified as primary, when no specific cause has been identified and is usually associated with multiple genetic polymorphisms and various environmental factor interactions, and secondary when there are conditions with biological plausibility to cause hypertension. Traditional data in medical textbooks indicate that in 90-95% of cases, arterial hypertension is primary, while only a small percentage of cases have secondary hypertension. European guidelines for elevated blood pressure and hypertension from 2024 indicate a higher prevalence of secondary hypertension, ranging from 10-35% of cases. Secondary hypertension is still not fully understood and often remains undiagnosed. Identifying the underlying cause of secondary hypertension is crucial, as treating the root condition can significantly reduce the risk of heart disease, stroke, and improve overall quality of life. Obesity is a major global health problem and the prevalence of obesity is constantly increasing and simultaneously leads to an increase in the prevalence of both primary and secondary arterial hypertension. Some forms of secondary hypertension cause more severe cardiac damage than primary hypertension and are associated with a higher cardiovascular risk. Secondary hypertension is more often resistant hypertension, which means that it is difficult to achieve target blood pressure values. It is important to timely conduct appropriate examinations and begin treatment promptly.

Introduction: Parkinson's disease is an idiopathic, slow progressive neurodegenerative condition with the loss of dopaminergic neurons in the substantia nigra compacta of the midbrain. Due to cardiovascular dysautonomia and impaired baroreflex function in Parkinson's disease, the development of orthostatic hypotension is most common, along with increased blood pressure variability, supine hypertension, nocturnal hypertension, etc. Orthostatic hypotension in Parkinson's disease increases the risk of developing coronary heart disease, myocardial infarction, and the risk of overall, and cardiovascular mortality. Case report: Orthostatic hypotension in Parkinson's disease is associated with an increased risk of gait disturbances, loss of balance, falls resulting in injuries and limb fractures, and mortality. In this paper, we presented a patient who had previously been treated for arterial hypertension, with the current clinical presentation of symptomatic orthostatic hypotension in Parkinson's disease. After neurological evaluation and the implementation of pharmacological and non-pharmacological therapy for orthostatic hypotension, gradual improvement and stabilization of blood pressure values are achieved, along with a reduction in orthostatic hypotension symptoms and a decrease in subjective discomfort. Conclusion: In the presence of orthostatic hypotension in Parkinson's disease, in addition to pharmacological therapy, nonpharmacological treatment measures are very important for stabilizing blood pressure values and reducing the symptoms of orthostatic hypotension.

Introduction: Arterial hypertension is a major cardiovascular risk factor affecting about 10-40% of the adult population. Secondary endocrine hypertension most often results from excessive aldosterone secretion. Complications related to excessive aldosterone secretion include atrial fibrillation, myocardial infarction, myocardial fibrosis, left ventricular hypertrophy, stroke, and increased cardiovascular mortality. Case report: This report presents a hypotensive woman with hypertensive reactions, newly diagnosed unilateral hyperplasia of the left adrenal gland and secondary hyperaldosteronism. Due to good blood pressure and normalized electrolyte status as a result of antihypertensive drug therapy and absence of damage to target organs, surgical treatment of unilateral adrenal hyperplasia was postponed. Conclusion: In case of midlife and late-life hypertension, it is necessary to consider a cause in the patient's endocrine system. AUTHORS SUMMARY SRPSKI 2021; 50 (1,2) 51-54